Townsquare Capital LLC Acquires 109,217 Shares of Haleon plc (NYSE:HLN)

Townsquare Capital LLC boosted its holdings in Haleon plc (NYSE:HLN) by 29.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 475,618 shares of the company’s stock after purchasing an additional 109,217 shares during the period. Townsquare Capital LLC’s holdings in Haleon were worth $5,032,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of HLN. FMR LLC boosted its holdings in shares of Haleon by 5.8% in the 3rd quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after buying an additional 5,768,117 shares during the last quarter. Sculptor Capital LP boosted its stake in Haleon by 67.8% in the second quarter. Sculptor Capital LP now owns 8,887,098 shares of the company’s stock valued at $73,407,000 after acquiring an additional 3,592,000 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of Haleon by 8.6% during the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company’s stock valued at $344,888,000 after acquiring an additional 3,307,009 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Haleon by 95.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,954,304 shares of the company’s stock worth $16,143,000 after purchasing an additional 954,622 shares during the last quarter. Finally, Natixis Advisors LLC raised its holdings in shares of Haleon by 142.5% in the 3rd quarter. Natixis Advisors LLC now owns 1,473,767 shares of the company’s stock worth $15,593,000 after purchasing an additional 866,070 shares during the period. Institutional investors own 6.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on HLN shares. Morgan Stanley increased their price objective on Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a report on Friday, September 20th. Berenberg Bank assumed coverage on Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Finally, UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $10.95.

Haleon Price Performance

Shares of NYSE HLN opened at $9.72 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. Haleon plc has a fifty-two week low of $7.89 and a fifty-two week high of $10.80. The stock has a market cap of $44.00 billion, a PE ratio of 28.59, a price-to-earnings-growth ratio of 2.89 and a beta of 0.30. The stock has a fifty day moving average of $9.95 and a 200-day moving average of $9.41.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.